Enadenotucirev - PsiOxus Therapeutics

Drug Profile

Enadenotucirev - PsiOxus Therapeutics

Alternative Names: Ad11/Ad3 chimeric group B adenovirus; ColoAd-1; EnAd; Oncolytic Ad11/Ad3 chimeric group B adenovirus

Latest Information Update: 02 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PsiOxus Therapeutics
  • Developer Merck & Co; PsiOxus Therapeutics
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Bladder cancer; Colorectal cancer; Non-small cell lung cancer; Ovarian cancer; Renal cancer; Urogenital cancer
  • Phase I Solid tumours
  • Preclinical Cancer

Most Recent Events

  • 07 Oct 2016 Full study efficacy and adverse events data from the phase I/II EVOLVE trial in Colorectal cancer, Non-small cell lung cancer, Bladder cancer and Renal cancer (Metastatic disease) presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
  • 30 Jun 2016 PsiOxus and Bristol-Myers Squibb agree to co-develop enadenotucirev for Solid tumours
  • 30 Jun 2016 PsiOxus plans a phase I trial for Solid tumours (Late stage disease, Combination therapy)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top